IC
SRPT icon

Ikarian Capital’s Sarepta Therapeutics SRPT Stock Holding History

Ikarian Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-101,800
Closed -$9.82M – 177
2023
Q4 		$9.82M Buy
101,800
+98,127
+2,672% +$9.41M 0.92% 36
2023
Q3 		$44.5M Sell
3,673
-118,427
-97% -$13.4M 5.36% 2
2023
Q2 		$14M Sell
122,100
-149,200
-55% -$19.2M 2.23% 9
2023
Q1 		$37.4M Buy
+271,300
New +$35.2M 8.48% 1
2021
Q2 		– Sell
-455,900
Closed -$34M – 278
2021
Q1 		$34M Sell
455,900
-415,000
-48% -$38.3M 1.14% 20
2020
Q4 		$148M Buy
870,900
+340,800
+64% +$50.5M 6.55% 2
2020
Q3 		$74.4M Buy
+530,100
New +$80.6M 5.39% 4

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Ikarian Capital's SRPT Position: Q3 2025 in Review

Ikarian Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 449,087 shares — an estimated $8.01M sold.

Ikarian Capital first reported a position in SRPT in Q1 2021 and held it in 13 quarters. The position peaked at $32.2M in Q2 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Ikarian Capital reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ikarian Capital sold 449,087 Sarepta Therapeutics shares in Q3 2025, an estimated $8.01M.
  • Ikarian Capital first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 13 quarters.
  • Ikarian Capital's Sarepta Therapeutics position peaked at $32.2M in Q2 2024.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Ikarian Capital's 13F filing for Q3 2025, filed 14 Nov 2025.